Condition Focus: Pathological Fibrosis — Anti-Fibrotic Mechanisms via TGF-β1 and Smad Signalling
Tophi — the characteristic chalky white deposits of chronic gout — are not simply piles of urate crystals. They are complex granulomatous structures surrounded by fibrotic tissue: dense, scarlike collagen deposited by activated fibroblasts. As tophi grow, this fibrotic shell can damage surrounding tissue, compress nerves, erode bone, and permanently alter joint architecture. Any therapy targeting chronic tophaceous gout needs to address this fibrotic component.
This 2025 comprehensive review in Frontiers in Medicine examines PBM’s anti-fibrotic properties in the context of keloid management — pathological scarring that shares key molecular features with tophaceous fibrosis. The review identifies TGF-β1 suppression as the primary anti-fibrotic mechanism: PBM reduces TGF-β1 expression, which in turn decreases collagen I and III synthesis by fibroblasts. The Smad signalling pathway (TGF-β1’s intracellular relay) is also modulated, and fibroblast apoptosis (programmed cell death of excess fibrotic cells) is promoted.
The anti-fibrotic effect operates alongside PBM’s anti-inflammatory and immunomodulatory effects — meaning a single intervention addresses both the inflammatory trigger and the fibrotic consequence. This is particularly relevant for chronic gout, where active inflammation and established fibrosis coexist in the same joints.
G.O.A.T. for Gout Alignment:
The anti-fibrotic pathways identified here (TGF-β1↓, collagen↓, Smad modulation) are relevant to the G.O.A.T.’s potential for chronic tophaceous gout management. While the device’s primary positioning targets acute flare relief, the anti-fibrotic evidence supports a broader role in long-term joint remodeling during maintenance therapy.
Link to original research here
Editor’s note: The transcriptome-level anti-fibrotic evidence is provided by Jagdeo et al 2021, which identified MMP1 and PRSS35 as key anti-fibrotic genes activated by PBM. The myofibroblast transition inhibition is detailed in PBM and Fibrosis Prevention 2025. The dual anti-inflammatory + anti-fibrotic effect is demonstrated in a lung model by Brochetti et al 2017. The cartilage matrix that fibrosis can replace is explored in PBM in Cartilage Regeneration 2025.
Related Articles
- Transcriptome Analysis: Red Light Activates Anti-Fibrotic Genes – Jagdeo et al 2021
- PBM as Prevention/Treatment for Fibrosis – 2025
- PBM Improves Inflammatory and Fibrotic Parameters – Brochetti et al 2017
- PBM in Promoting Cartilage Regeneration – 2025
- PBM, Cells of Connective Tissue and Repair – Houreld et al 2022
Key Takeaways
- PBM reduces TGF-β1, collagen I/III synthesis, and Smad signalling — the core fibrotic pathway
- Fibroblast apoptosis promoted — reducing excess fibrotic tissue
- Tophi are surrounded by fibrotic tissue — anti-fibrotic effects directly relevant to chronic gout
- Dual anti-inflammatory + anti-fibrotic action addresses both active disease and established damage
Study Overview
| Study Type: | Comprehensive review |
| Wavelength(s): | Red to NIR (600–1100 nm) |
| Treatment Protocol: | Varies across reviewed studies |
| Sample Size: | Review of keloid and fibrosis studies |
| Primary Outcome: | TGF-β1↓, collagen↓, Smad↓, fibroblast apoptosis↑ |
Full Citation
PBM therapy in keloid management: a comprehensive review. (2025). Frontiers in Medicine, 12. View Publication
